MX2020000154A - Composiciones y métodos para inhibir la expresión de hmgb1. - Google Patents
Composiciones y métodos para inhibir la expresión de hmgb1.Info
- Publication number
- MX2020000154A MX2020000154A MX2020000154A MX2020000154A MX2020000154A MX 2020000154 A MX2020000154 A MX 2020000154A MX 2020000154 A MX2020000154 A MX 2020000154A MX 2020000154 A MX2020000154 A MX 2020000154A MX 2020000154 A MX2020000154 A MX 2020000154A
- Authority
- MX
- Mexico
- Prior art keywords
- hmgb1 expression
- compositions
- methods
- oligonucleotides
- hepatocytes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 abstract 3
- 102000055207 HMGB1 Human genes 0.000 abstract 3
- 108700010013 HMGB1 Proteins 0.000 abstract 3
- 101150021904 HMGB1 gene Proteins 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
- 210000003494 hepatocyte Anatomy 0.000 abstract 2
- 101710163270 Nuclease Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762526971P | 2017-06-29 | 2017-06-29 | |
| PCT/US2018/040410 WO2019006375A1 (en) | 2017-06-29 | 2018-06-29 | COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000154A true MX2020000154A (es) | 2020-07-22 |
Family
ID=64735107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000154A MX2020000154A (es) | 2017-06-29 | 2018-06-29 | Composiciones y métodos para inhibir la expresión de hmgb1. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10675295B2 (enExample) |
| EP (1) | EP3645013A4 (enExample) |
| JP (1) | JP2020529197A (enExample) |
| KR (1) | KR20200023427A (enExample) |
| CN (1) | CN111050776A (enExample) |
| AU (1) | AU2018294415A1 (enExample) |
| CA (1) | CA3068630A1 (enExample) |
| IL (2) | IL271680B (enExample) |
| MX (1) | MX2020000154A (enExample) |
| WO (1) | WO2019006375A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10675295B2 (en) | 2017-06-29 | 2020-06-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting HMGB1 expression |
| CN111971051A (zh) * | 2018-04-13 | 2020-11-20 | 迪克纳制药公司 | 用增加tm的核苷酸修饰的双链核酸抑制剂分子 |
| JP7535047B2 (ja) * | 2018-12-12 | 2024-08-15 | ディセルナ ファーマシューティカルズ インコーポレイテッド | トリループを含む二本鎖核酸インヒビター分子 |
| IL284327B2 (en) * | 2018-12-28 | 2024-11-01 | Dicerna Pharmaceuticals Inc | Compositions and methods for inhibiting hmgb1 expression |
| KR20230171431A (ko) * | 2021-04-14 | 2023-12-20 | 다이서나 파마수이티컬, 인크. | Pnpla3 발현을 조절하기 위한 조성물 및 방법 |
| IL307154A (en) * | 2021-04-19 | 2023-11-01 | Novo Nordisk As | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression |
| CN117280031A (zh) * | 2021-04-19 | 2023-12-22 | 诺和诺德股份有限公司 | 用于抑制核受体亚家族1组h成员3（nr1h3）表达的组合物和方法 |
| KR20240046843A (ko) * | 2021-08-25 | 2024-04-11 | 노보 노르디스크 에이/에스 | 알파-1 항트립신 발현을 억제하기 위한 조성물 및 방법 |
| JP7877458B2 (ja) * | 2021-12-01 | 2026-06-22 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ａｐｏｃ３発現を調節するための組成物及び方法 |
| TWI868755B (zh) * | 2022-06-24 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 |
| CN117264954A (zh) * | 2022-09-20 | 2023-12-22 | 北京福元医药股份有限公司 | 用于抑制hmgb1基因表达的双链核糖核酸及其修饰物、缀合物和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US20080311122A1 (en) | 2005-11-28 | 2008-12-18 | Medimmune, Llc | Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof |
| US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| US20110081362A1 (en) * | 2008-01-31 | 2011-04-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| WO2010033225A2 (en) * | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| WO2011007876A1 (ja) * | 2009-07-16 | 2011-01-20 | Ｎｅｃソフト株式会社 | Ｈｍｇｂ１結合核酸分子およびその用途 |
| EP2617426B1 (en) * | 2010-09-17 | 2016-08-10 | Japan Science and Technology Agency | Inhibitor of hmgb protein-mediated immune response activation |
| WO2014028494A1 (en) * | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Detecting and treating liver damage |
| US10351854B2 (en) * | 2014-10-10 | 2019-07-16 | Dicerna Pharmaceuticals, Inc. | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
| EP3865576A1 (en) * | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| WO2017079227A1 (en) * | 2015-11-05 | 2017-05-11 | University Of Connecticut | Compositions and methods for the treatment of liver fibrosis |
| CN106244589A (zh) * | 2016-08-01 | 2016-12-21 | 中国人民解放军第四军医大学 | 靶向hmgb1基因的rna干扰片段及其应用 |
| US10675295B2 (en) | 2017-06-29 | 2020-06-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting HMGB1 expression |
| WO2019126097A1 (en) * | 2017-12-18 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof |
| US11883019B2 (en) | 2017-12-21 | 2024-01-30 | Cilag Gmbh International | Stapling instrument comprising a staple feeding system |
| IL284327B2 (en) | 2018-12-28 | 2024-11-01 | Dicerna Pharmaceuticals Inc | Compositions and methods for inhibiting hmgb1 expression |
-
2018
- 2018-06-29 US US16/024,355 patent/US10675295B2/en active Active
- 2018-06-29 KR KR1020207002542A patent/KR20200023427A/ko not_active Ceased
- 2018-06-29 CN CN201880056295.0A patent/CN111050776A/zh active Pending
- 2018-06-29 MX MX2020000154A patent/MX2020000154A/es unknown
- 2018-06-29 IL IL271680A patent/IL271680B/en unknown
- 2018-06-29 JP JP2019572382A patent/JP2020529197A/ja active Pending
- 2018-06-29 EP EP18824412.3A patent/EP3645013A4/en active Pending
- 2018-06-29 AU AU2018294415A patent/AU2018294415A1/en not_active Abandoned
- 2018-06-29 WO PCT/US2018/040410 patent/WO2019006375A1/en not_active Ceased
- 2018-06-29 CA CA3068630A patent/CA3068630A1/en active Pending
- 2018-06-29 IL IL295086A patent/IL295086A/en unknown
-
2020
- 2020-04-30 US US16/863,081 patent/US11478501B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10675295B2 (en) | 2020-06-09 |
| EP3645013A4 (en) | 2021-07-21 |
| IL295086A (en) | 2022-09-01 |
| JP2020529197A (ja) | 2020-10-08 |
| CN111050776A (zh) | 2020-04-21 |
| US20190000870A1 (en) | 2019-01-03 |
| KR20200023427A (ko) | 2020-03-04 |
| AU2018294415A1 (en) | 2020-01-16 |
| US11478501B2 (en) | 2022-10-25 |
| IL271680B (en) | 2022-09-01 |
| IL271680A (en) | 2020-02-27 |
| US20200297754A1 (en) | 2020-09-24 |
| WO2019006375A1 (en) | 2019-01-03 |
| EP3645013A1 (en) | 2020-05-06 |
| CA3068630A1 (en) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011006A (es) | Pcsk9 dirigido a oligonucleótidos para el tratamiento de la hipercolesterolemia y afecciones relacionadas. | |
| MX2020007582A (es) | Composiciones y metodos para inhibir la expresion de aldehido deshidrogenasa mitocondrial 2 (aldh2). | |
| MX2021007855A (es) | Composiciones y metodos para inhibir la expresion de hmgb1. | |
| IL273461A (en) | Changing the specificity of non-coding RNA molecules for silencing gene expression in eukaryotic cells | |
| MX2020011806A (es) | Agentes de iarn para infeccion causada por el virus de la hepatitis b. | |
| MX2020009072A (es) | Composiciones y metodos para inhibir la expresion de gys2. | |
| GB2542653A (en) | Methods and compositions for treating cells for transplant | |
| NZ727481A (en) | Methods and compositions for modifying a targeted locus | |
| FI3604532T3 (fi) | Uusia crispr-entsyymejä ja järjestelmiä | |
| EP4177346A3 (en) | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases | |
| HK1208361A1 (en) | Multi-target modulation for treating fibrosis and inflammatory conditions | |
| WO2009006577A3 (en) | Compositions and methods for inhibiting ezh2 | |
| MX2015011943A (es) | Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados. | |
| WO2017059223A3 (en) | Compositions and methods for inhibiting gene expression of lpa | |
| PH12014502445A1 (en) | Targeted modification of malate dehydrogenase | |
| WO2015200555A3 (en) | Rna modification to engineer cas9 activity | |
| HK1252970A1 (zh) | 确定的多偶联寡核苷酸 | |
| WO2015023975A8 (en) | Compositions and methods for modulating rna | |
| WO2011153323A3 (en) | Compositions and methods directed to treating liver fibrosis | |
| MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
| WO2013112699A3 (en) | Proteasome activity enhancing compounds | |
| WO2017197141A3 (en) | Targeted treatment of androgenic alopecia | |
| WO2008092099A3 (en) | Compositions and methods for treating hematopoietic malignancies | |
| MX2020009074A (es) | Metodos y composiciones para el tratamiento de condiciones asociadas a la deficiencia del conducto biliar. | |
| CN106471121A8 (zh) | 减少功能蛋白的水平基因转移 |